



5th July 2024

Shareholder Update

Dr Richard Mollard appointed as Chief Scientific Officer and Chief Commercial Officer

Myopharm Limited is pleased to advise that Dr Richard Mollard has been appointed as Chief Scientific Officer and Chief Commercial Officer.

Dr Mollard is a highly experienced and respected pharmaceutical and commercialisation executive with over 20 years of leading biotechnology and international commercial experience. Importantly, Dr Mollard has a proven background in repurposed drug development. Bringing an impeccable track record at driving and building many Australian and International biotechnology businesses and market capitalisations and attracting notable research grants in the areas of Respiratory and Motor Neurone Disease (MND).

Dr Richard Mollard received his Doctor of Philosophy (PhD) in 1996 in Molecular Biology and Developmental Genetics at the Faculty of Medicine, Monash university, Melbourne. He also received a Master of Business Administration (MBA) from the Melbourne Business School as well as an Accreditation from the University of St Gallen's Graduate School of Business, Economic, Law and Social Sciences, Switzerland. Dr Mollard is the author of 38 peer-reviewed and invited scientific journal publications and is currently an Honorary Fellow with the Department of Veterinary Sciences and Agriculture at the University of Melbourne.

On behalf of the Myopharm Board of Directors "Dr Mollard is a very welcome appointment and we look forward to Richard playing a key role in the next exciting stages of Myopharm's commercial formulation development".

For further details please contact:

Karinza Phoenix
Myopharm Limited
Executive Chair & Chief Executive Officer
kphoenix@myopharm.com

Release authorised by the Board of Directors of Myopharm Limited

For Investor Enquiries, please get in touch with us at Investor@myopharm.com